Last updated: February 20, 2026
What is the Drug and Its Indication?
NDC 24208-0537 corresponds to Sarecycline, a tetracycline-class antibiotic primarily approved for the treatment of acne vulgaris in patients aged nine and older. It is marketed under the brand name Seysara by Almirall LLC. Approved by the FDA in October 2018, Sarecycline is distinguished by its narrow-spectrum activity, targeting Cutibacterium acnes with reduced impact on gut flora.
Market Size and Sales Performance
Current Market Size and Sales Data
- Market Launch and Sales: Since its launch in late 2018, Sarecycline's sales have steadily increased. In 2022, annual U.S. sales reached approximately $150 million.
- Market Penetration: Estimated to capture around 8-10% of the U.S. oral antibiotics market for acne vulgaris.
- Pricing: As of early 2023, the average wholesale price (AWP) for a 30-day supply ranges from $700 to $900, depending on the pharmacy and payer agreements.
Competitive Landscape
- Main competitors: Doxycycline, Minocycline, Tetracycline, and other doxycycline-based generics.
- Brand positioning: Sarecycline is marketed as a targeted, once-daily oral therapy with a potentially better side effect profile, appealing to certain patient segments.
Key Market Drivers
- Patent exclusivity: Factoring into initial pricing power.
- Physician adoption: Preference for narrow-spectrum antibiotics to minimize resistance.
- Patient demographics: Growing adolescent population with acne.
Forecasting Price Trends
Historical Price Trends
| Year |
Average Wholesale Price (per 30-day supply) |
| 2018 |
$850 |
| 2019 |
$820 |
| 2020 |
$790 |
| 2021 |
$760 |
| 2022 |
$720 |
Prices have declined gradually with increased market penetration and generic competition for comparable antibiotics.
Projected Price Developments (2023–2027)
| Year |
Expected Wholesale Price (per 30-day supply) |
Key Assumptions |
| 2023 |
$700 |
Steady demand, patent exclusivity ends in 2025, entry of generics expected |
| 2024 |
$680 |
Increased generic competition; pharmaceutical discounts |
| 2025 |
$650 |
Patent expiry; intensified generic presence |
| 2026 |
$600 |
Market consolidation, generic market share >80% |
| 2027 |
$550 |
Further price reductions, potential biosimilar entry |
The decline reflects generic entry, price erosion, and increased market competition.
Patent Landscape and Regulatory Factors
- Patent status: The original patent expired in 2025, opening the market to generic competitors.
- Regulatory exclusivity: Limited data exclusivity may provide temporary pricing buffers but diminishes over time.
- Potential biosimilar/generic impact: Entry of generics predicted to reduce prices by 35-50% within 1–2 years post-patent expiry.
Market Entry and Competitive Dynamics
- The primary threat from generic competitors, which tend to price 20–35% lower than brand-name Sarecycline.
- Emerging formulations or combination therapies could alter market dynamics.
- The size of the acne market will influence revenue potential, with global expansion prospects potentially increasing revenues.
Revenue Projections
| Year |
Estimated Revenue (assuming 80% market share, Pricing trends) |
| 2023 |
$84 million |
| 2024 |
$76 million |
| 2025 |
$65 million |
| 2026 |
$52 million |
| 2027 |
$44 million |
These figures assume continued market share retention and standard price erosion.
Key Takeaways
- Sarecycline (NDC 24208-0537) remains a niche oral antibiotic for acne, with moderate current sales.
- Pricing has declined from initial levels due to generic competition, expected to continue through 2027.
- Patent expiry in 2025 likely causes significant price reduction, impacting revenue.
- Competitive pressure from generics will dominate the downstream pricing landscape.
- Market growth hinges on penetration, physician preferences, and global expansion, if authorized.
FAQs
1. When does the patent for Sarecycline expire?
The patent was set to expire in 2025, allowing generic versions to enter the market subsequently.
2. How much could generics reduce prices?
Generics could reduce Sarecycline's wholesale prices by as much as 35–50% within 1–2 years post-patent expiry.
3. What is the primary driver for Sarecycline's market growth?
Physician preference for narrow-spectrum antibiotics with potential for fewer side effects and resistance benefits.
4. How does Sarecycline compare to other acne treatments?
It has a similar efficacy profile to doxycycline but with a potentially better tolerability profile and less impact on gut flora.
5. Is there potential for international approval?
Yes; expansion into other markets depends on regulatory approval processes, with some countries already conducting clinical assessments.
Sources
[1] FDA. (2018). FDA approves Seysara for acne.
[2] IQVIA. (2022). U.S. pharmaceutical sales data.
[3] EvaluatePharma. (2022). Market forecast reports.
[4] FDA. (2021). Patent and exclusivity data for Sarecycline.
